Travere Free Cash Flow Yield vs Ev To Free Cash Flow Analysis

TVTX Stock

USD 18.86 0.11 0.58%

Travere Therapeutics financial indicator trend analysis is much more than just breaking down Travere Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Travere Therapeutics is a good investment. Please check the relationship between Travere Therapeutics Free Cash Flow Yield and its Ev To Free Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Free Cash Flow Yield vs Ev To Free Cash Flow

Free Cash Flow Yield vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Travere Therapeutics Free Cash Flow Yield account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Travere Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow is -0.33. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Travere Therapeutics, assuming nothing else is changed. The correlation between historical values of Travere Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Travere Therapeutics are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Free Cash Flow Yield i.e., Travere Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.33

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from Travere Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Travere Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.At this time, Travere Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 210.7 K in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 113.4 M in 2025.

	2022	2023	2024	2025 (projected)
Research Development	235.8M	245.0M	281.7M	295.8M
Depreciation And Amortization	20.7M	38.5M	44.3M	46.5M

Research Development Depreciation And Amortization

Travere Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant And Equipment Net	Current Deferred Revenue	Non Current Assets Total	Non Currrent Assets Other	Other Current Assets	Intangible Assets	Short Term Investments	Property Plant And Equipment Gross
Total Assets		0.74	0.77	0.78	0.79	0.6	-0.74	0.64	0.79	0.9	0.93	0.55	0.85	0.81	0.84	0.91	0.1	0.85	0.66	0.11	0.92	0.42	0.7	0.8	0.87	0.65
Short Long Term Debt Total	0.74		0.86	0.92	0.29	0.97	-0.97	0.87	0.48	0.91	0.79	0.55	0.97	0.96	0.97	0.9	-0.14	0.91	0.89	-0.31	0.58	0.74	0.88	0.42	0.94	0.92
Other Current Liab	0.77	0.86		0.92	0.49	0.81	-0.86	0.89	0.47	0.87	0.79	0.51	0.88	0.93	0.91	0.89	0.0	0.96	0.8	-0.07	0.72	0.8	0.96	0.58	0.9	0.84
Total Current Liabilities	0.78	0.92	0.92		0.45	0.87	-0.88	0.89	0.52	0.9	0.82	0.49	0.91	0.94	0.95	0.91	0.19	0.97	0.8	-0.01	0.72	0.7	0.9	0.6	0.92	0.84
Total Stockholder Equity	0.79	0.29	0.49	0.45		0.11	-0.26	0.35	0.75	0.65	0.58	0.28	0.45	0.47	0.46	0.68	0.24	0.56	0.24	0.46	0.85	0.1	0.4	0.85	0.59	0.24
Net Debt	0.6	0.97	0.81	0.87	0.11		-0.93	0.86	0.25	0.8	0.67	0.52	0.9	0.9	0.91	0.79	-0.19	0.83	0.83	-0.4	0.43	0.79	0.88	0.26	0.86	0.88
Retained Earnings	-0.74	-0.97	-0.86	-0.88	-0.26	-0.93		-0.83	-0.51	-0.87	-0.83	-0.58	-0.94	-0.95	-0.94	-0.86	0.2	-0.89	-0.93	0.37	-0.54	-0.77	-0.86	-0.37	-0.89	-0.94
Accounts Payable	0.64	0.87	0.89	0.89	0.35	0.86	-0.83		0.35	0.84	0.66	0.48	0.82	0.9	0.85	0.83	-0.11	0.87	0.73	-0.25	0.51	0.82	0.91	0.37	0.88	0.81
Cash	0.79	0.48	0.47	0.52	0.75	0.25	-0.51	0.35		0.73	0.75	0.34	0.62	0.59	0.61	0.71	0.13	0.62	0.56	0.18	0.76	0.11	0.32	0.73	0.62	0.49
Cash And Short Term Investments	0.9	0.91	0.87	0.9	0.65	0.8	-0.87	0.84	0.73		0.86	0.54	0.96	0.96	0.96	1.0	-0.04	0.95	0.82	-0.06	0.79	0.61	0.85	0.67	0.99	0.84
Common Stock Total Equity	0.93	0.79	0.79	0.82	0.58	0.67	-0.83	0.66	0.75	0.86		0.54	0.87	0.84	0.87	0.86	0.09	0.86	0.76	-0.03	0.81	0.51	0.7	0.7	0.83	0.73
Common Stock Shares Outstanding	0.55	0.55	0.51	0.49	0.28	0.52	-0.58	0.48	0.34	0.54	0.54		0.56	0.57	0.55	0.54	-0.15	0.5	0.55	-0.21	0.39	0.44	0.53	0.25	0.55	0.56
Non Current Liabilities Total	0.85	0.97	0.88	0.91	0.45	0.9	-0.94	0.82	0.62	0.96	0.87	0.56		0.97	0.99	0.95	-0.09	0.94	0.87	-0.21	0.72	0.67	0.87	0.59	0.96	0.88
Other Stockholder Equity	0.81	0.96	0.93	0.94	0.47	0.9	-0.95	0.9	0.59	0.96	0.84	0.57	0.97		0.98	0.96	-0.12	0.97	0.91	-0.21	0.67	0.78	0.93	0.52	0.97	0.93
Total Liab	0.84	0.97	0.91	0.95	0.46	0.91	-0.94	0.85	0.61	0.96	0.87	0.55	0.99	0.98		0.96	-0.02	0.96	0.87	-0.16	0.74	0.69	0.89	0.6	0.97	0.88
Total Current Assets	0.91	0.9	0.89	0.91	0.68	0.79	-0.86	0.83	0.71	1.0	0.86	0.54	0.95	0.96	0.96		-0.01	0.96	0.81	-0.03	0.82	0.62	0.87	0.7	0.99	0.83
Short Term Debt	0.1	-0.14	0.0	0.19	0.24	-0.19	0.2	-0.11	0.13	-0.04	0.09	-0.15	-0.09	-0.12	-0.02	-0.01		0.07	-0.2	0.76	0.38	-0.36	-0.07	0.49	-0.07	-0.21
Common Stock	0.85	0.91	0.96	0.97	0.56	0.83	-0.89	0.87	0.62	0.95	0.86	0.5	0.94	0.97	0.96	0.96	0.07		0.84	-0.02	0.79	0.72	0.92	0.65	0.95	0.86
Property Plant And Equipment Net	0.66	0.89	0.8	0.8	0.24	0.83	-0.93	0.73	0.56	0.82	0.76	0.55	0.87	0.91	0.87	0.81	-0.2	0.84		-0.31	0.47	0.69	0.79	0.3	0.82	0.99
Current Deferred Revenue	0.11	-0.31	-0.07	-0.01	0.46	-0.4	0.37	-0.25	0.18	-0.06	-0.03	-0.21	-0.21	-0.21	-0.16	-0.03	0.76	-0.02	-0.31		0.36	-0.54	-0.12	0.49	-0.11	-0.32
Non Current Assets Total	0.92	0.58	0.72	0.72	0.85	0.43	-0.54	0.51	0.76	0.79	0.81	0.39	0.72	0.67	0.74	0.82	0.38	0.79	0.47	0.36		0.27	0.61	0.96	0.75	0.45
Non Currrent Assets Other	0.42	0.74	0.8	0.7	0.1	0.79	-0.77	0.82	0.11	0.61	0.51	0.44	0.67	0.78	0.69	0.62	-0.36	0.72	0.69	-0.54	0.27		0.81	0.09	0.68	0.76
Other Current Assets	0.7	0.88	0.96	0.9	0.4	0.88	-0.86	0.91	0.32	0.85	0.7	0.53	0.87	0.93	0.89	0.87	-0.07	0.92	0.79	-0.12	0.61	0.81		0.45	0.9	0.85
Intangible Assets	0.8	0.42	0.58	0.6	0.85	0.26	-0.37	0.37	0.73	0.67	0.7	0.25	0.59	0.52	0.6	0.7	0.49	0.65	0.3	0.49	0.96	0.09	0.45		0.62	0.27
Short Term Investments	0.87	0.94	0.9	0.92	0.59	0.86	-0.89	0.88	0.62	0.99	0.83	0.55	0.96	0.97	0.97	0.99	-0.07	0.95	0.82	-0.11	0.75	0.68	0.9	0.62		0.85
Property Plant And Equipment Gross	0.65	0.92	0.84	0.84	0.24	0.88	-0.94	0.81	0.49	0.84	0.73	0.56	0.88	0.93	0.88	0.83	-0.21	0.86	0.99	-0.32	0.45	0.76	0.85	0.27	0.85

Click cells to compare fundamentals

Travere Therapeutics Account Relationship Matchups

Travere Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	607.4M	776.6M	672.6M	788.9M	907.2M	461.7M
Short Long Term Debt Total	215.7M	262.0M	407.5M	404.8M	465.5M	488.8M
Other Current Liab	80.5M	84.9M	104.0M	124.2M	142.9M	150.0M
Total Current Liabilities	92.7M	124.1M	142.2M	177.9M	204.6M	214.8M
Total Stockholder Equity	211.2M	302.1M	42.9M	200.8M	230.9M	168.0M
Net Debt	130.6M	96.2M	345.8M	346.6M	398.6M	418.5M
Retained Earnings	(585.9M)	(766.0M)	(1.0B)	(1.1B)	(1.0B)	(962.4M)
Accounts Payable	12.1M	15.1M	17.3M	41.7M	47.9M	50.3M
Cash	84.8M	165.8M	61.7M	58.2M	66.9M	58.0M
Cash And Short Term Investments	361.6M	552.9M	450.2M	566.9M	651.9M	684.5M
Common Stock Shares Outstanding	47.5M	59.8M	63.8M	74.3M	85.4M	45.7M
Liabilities And Stockholders Equity	607.4M	776.6M	672.6M	788.9M	907.2M	461.7M
Non Current Liabilities Total	303.6M	350.4M	487.6M	410.2M	471.7M	495.3M
Other Stockholder Equity	798.0M	1.1B	1.1B	1.3B	1.5B	1.6B
Total Liab	396.2M	474.5M	629.7M	588.1M	676.3M	710.1M
Total Current Assets	410.4M	582.8M	486.4M	616.8M	709.3M	744.8M
Short Term Debt	357K	7.8M	8.9M	4.9M	5.6M	8.9M
Property Plant And Equipment Net	9.4M	34.3M	30.0M	25.5M	29.4M	30.8M
Current Deferred Revenue	(357K)	16.3M	12.0M	7.1M	6.4M	11.3M
Non Current Assets Total	197.0M	193.8M	186.1M	172.1M	198.0M	169.6M
Non Currrent Assets Other	33.5M	11.1M	11.1M	42.2M	48.5M	50.9M
Other Current Assets	8.1M	6.7M	15.0M	19.3M	22.2M	23.3M
Intangible Assets	153.2M	148.4M	145.0M	103.7M	119.2M	140.4M
Short Term Investments	276.8M	387.1M	388.6M	508.7M	585.0M	614.2M
Property Plant And Equipment Gross	9.4M	34.3M	30.0M	33.0M	37.9M	39.8M
Accumulated Other Comprehensive Income	(902K)	(562K)	(2.9M)	(1.5M)	(1.3M)	(1.2M)
Net Receivables	33.1M	15.9M	16.6M	21.2M	19.1M	21.3M
Inventory	7.6M	7.3M	6.9M	9.4M	10.8M	6.0M
Other Liab	83.3M	59.9M	92.4M	84.5M	76.1M	67.7M
Net Tangible Assets	63.1M	57.1M	153.7M	(102.2M)	(92.0M)	(87.4M)
Other Assets	14.7M	7.8M	11.1M	36K	32.4K	30.8K
Long Term Debt	215.3M	226.6M	375.5M	377.3M	433.9M	257.7M
Net Invested Capital	426.6M	528.7M	418.4M	578.1M	664.8M	511.0M
Non Current Liabilities Other	88.2M	20.4M	73.6M	8.5M	7.6M	7.3M
Net Working Capital	317.7M	458.7M	344.3M	438.9M	504.7M	396.7M
Property Plant Equipment	2.9M	35.1M	11.1M	9.0M	10.4M	11.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Travere Stock Analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Travere Free Cash Flow Yield vs Ev To Free Cash Flow Analysis

Free Cash Flow Yield vs Ev To Free Cash Flow

Free Cash Flow Yield vs Ev To Free Cash Flow Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Ev To Free Cash Flow

Travere Therapeutics fundamental ratios Correlations

Travere Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Travere Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Travere Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Term Investments	+ 0.99	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Short Term Investments	+ 0.99	Total Current Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.98	Other Stockholder Equity

Retained Earnings	- 0.97	Short Long Term Debt Total
Other Stockholder Equity	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Non Current Liabilities Total	- 0.94	Retained Earnings
Property Plant And Equipment Net	- 0.93	Retained Earnings